House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Pulmonology

Global strategy for COPD diagnosis, management and prevention — 2026

GOLD · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

GOLD 2026 guides COPD diagnosis, risk assessment and individualized long-term and exacerbation care. An important change is that even one moderate or severe exacerbation in the previous year places a treatment-naive patient in group E; follow-up treatment is then driven by current symptoms and exacerbations rather than simply reusing the initial group.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Confirm obstruction and assess symptoms and risk

  • Consider COPD with chronic breathlessness, cough or sputum, recurrent lower respiratory infections or relevant exposures. Confirm the diagnosis in clinical context with post-bronchodilator FEV1/FVC below 0.7; symptoms or imaging alone are insufficient. [1]
  • For initial assessment, group E includes at least one moderate or severe exacerbation in the previous year, regardless of symptom burden. With no such exacerbation, the A/B symptom split uses mMRC 0–1 or CAAT below 10 for the lower-burden side and mMRC at least 2 or CAAT at least 10 for the higher-burden side. [1]
  • Assess comorbidities and reassess symptoms, exacerbations, treatment effects, inhaler technique, adherence and ongoing exposures. Repeat spirometry at least annually; unexplained breathlessness should prompt investigation for causes beyond COPD. [1]

Start maintenance treatment according to the initial assessment

  • For group A, offer a bronchodilator according to breathlessness response; a long-acting agent is preferred when affordable and available, except with very occasional symptoms. Continue when benefit is demonstrated, and provide a short-acting rescue bronchodilator for immediate relief. [1]
  • For group B, start LABA plus LAMA when available, affordable and tolerated. If dual treatment is unsuitable, select a single long-acting bronchodilator according to the individual’s symptom response, and assess contributing comorbidities. [1]
  • For group E, LABA plus LAMA is the preferred initial combination. Consider LABA/LAMA/ICS when blood eosinophils are at least 300 cells/µL. GOLD labels this initial triple-treatment choice a practical recommendation; direct trials in newly diagnosed patients are lacking. [1]
  • LABA/ICS is generally not encouraged as the preferred COPD combination; when ICS is indicated, triple treatment is preferred. Coexisting asthma changes the pathway: follow asthma treatment principles and include ICS. [1]

Adjust existing treatment by the problem that persists

  • Before escalating, check adherence, device technique and interfering comorbidities. Use the follow-up algorithm for anyone already on maintenance therapy; if both breathlessness and exacerbations need attention, follow the exacerbation pathway. [1]
  • Persistent breathlessness or exercise limitation on one long-acting bronchodilator warrants LABA plus LAMA. If dual therapy does not help, consider changing device or molecule, pulmonary rehabilitation and, where available, ensifentrine; investigate other causes of dyspnoea. [1]
  • An exacerbation on bronchodilator monotherapy warrants escalation to LABA/LAMA. A moderate or severe exacerbation on LABA/LAMA supports considering triple therapy: ICS benefit may begin at eosinophils at least 100 cells/µL and tends to increase with higher counts. [1]
  • For exacerbations persisting on LABA/LAMA with eosinophils below 100 cells/µL, consider azithromycin in people not currently smoking, accounting for antimicrobial resistance. Roflumilast is an option with FEV1 below 50%, chronic bronchitis symptoms and a prior exacerbation requiring hospitalization. [1]
  • With exacerbations continuing despite triple therapy and eosinophils at least 300 cells/µL, consider specialist assessment for dupilumab when chronic bronchitis is present, or mepolizumab with or without chronic bronchitis. These are selected add-on options, not substitutes for the preceding treatment assessment. [1]
  • Do not withdraw ICS from triple therapy without a reason such as inappropriate initiation, lack of response, significant adverse effects or severe/recurrent pneumonia. Weigh risks under supervision; withdrawal is more likely to trigger exacerbations when eosinophils are at least 300 cells/µL. [1]
  • A patient without asthma already well controlled on LABA/ICS may continue it. With further exacerbations, escalate to triple therapy if eosinophils are at least 100 cells/µL or switch to LABA/LAMA if below that level; major symptoms require reassessment of the bronchodilator regimen and previous ICS response. [1]

Provide prevention, rehabilitation and indicated oxygen

  • Actively support smoking cessation with counselling and appropriate pharmacotherapy. Keep vaccinations current under local recommendations, including influenza, pneumococcal, COVID-19 and eligible RSV vaccination. Encourage structured pulmonary rehabilitation, especially with high symptoms or exacerbation risk. [1]
  • Assess long-term oxygen in stable severe resting hypoxaemia: PaO2 at or below 55 mmHg or arterial saturation at or below 88%, confirmed twice over three weeks. The alternative criterion is PaO2 55–60 mmHg or saturation 88% with pulmonary hypertension, oedema suggesting cardiac failure, or haematocrit above 55%. [1]
  • Do not routinely prescribe long-term oxygen for moderate resting or exercise-related desaturation. Reassess oxygen eligibility after 60–90 days with blood gases or saturation. Consider palliative symptom support and selected lung-volume-reduction procedures individually in advanced disease. [1]

Treat deterioration and recognize respiratory failure

  • Assess pneumonia, pulmonary embolism, acute heart failure and pneumothorax as alternative or additional explanations for apparent COPD exacerbation. Hypoxaemia needs controlled oxygen and assessment for life-threatening illness, gas-exchange failure and need for monitored ventilatory support. [1]
  • Use a short-acting beta agonist, with or without a short-acting anticholinergic, as initial bronchodilator treatment. For significant exacerbations requiring systemic steroids, the recommended course is prednisone-equivalent 40 mg daily for 5 days; oral prednisolone is as effective as IV administration. Methylxanthines are not recommended. [1]
  • During an exacerbation, antibiotics are indicated with increased sputum purulence plus another listed symptom (increased dyspnoea, fever or sputum volume), a prior positive exacerbation sputum culture, or need for invasive/noninvasive ventilation. Choose against local resistance patterns and obtain cultures in higher-risk presentations. [1]
  • Antibiotic treatment should be brief and appropriate to the setting: the detailed text recommends no more than 5 days for outpatients and describes 5–7 days overall, while the chapter summary gives 5 days. Use the relevant setting and clinical assessment rather than treating these differing descriptions as an automatic extension rule. [1]
  • Respiratory-support selection requires blood-gas and clinical assessment. The acute-care figure distinguishes high-flow nasal oxygen for hypoxaemic failure from NIV for hypercapnic failure or failure to respond to high-flow therapy, unless NIV is contraindicated. Provide close monitoring and prompt escalation if support fails. [1]
  • During a COPD exacerbation, NIV indications include respiratory acidosis with PaCO2 at least 45 mmHg and arterial pH at most 7.35, severe dyspnoea with signs of respiratory muscle fatigue/increased work, or persistent hypoxaemia despite supplemental oxygen. Invasive ventilation may be needed for persistent life-threatening hypoxaemia despite HFNT/NIV, arrest, diminished consciousness, massive aspiration or persistent vomiting, or severe haemodynamic instability unresponsive to fluids and vasoactive drugs. [1]
  • Plan discharge with appropriate long-term pharmacological and non-pharmacological therapy and rehabilitation. When possible, review within one month and again at three months to assess recovery, symptoms, spirometry and longer-term oxygen needs. [1]

Limitations and use

  • This focused summary covers selected diagnosis, initial and follow-up treatment, oxygen and exacerbation recommendations. It is not the complete report, inhaler/device selection guide, oxygen titration protocol, ventilation prescription, biologic eligibility protocol or drug-safety checklist. Treatment availability, affordability and national approvals must be checked locally. Initial ABE treatment guidance and some escalation choices rely on practical interpretation rather than direct trials of every sequence.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Global strategy for COPD diagnosis, management and prevention — 2026

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
GOLD
Resource type
Clinical guideline · House clinical summary

Earlier House summaries: chronic obstructive pulmonary disease gold

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Confirm obstruction and assess symptoms and risk
  • Start maintenance treatment according to the initial assessment
  • Adjust existing treatment by the problem that persists
  • Provide prevention, rehabilitation and indicated oxygen
  • Treat deterioration and recognize respiratory failure
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House